Here you will find the recommendations we have made about the use of individual medicines in Lancashire.


Brand: Tertroxin®
Indication: Liothyronine as an add-on treatment for refractory hypothyroidism despite adequate monotherapy with levothyroxine
Disease category: Endocrine system
Commissioning responsibility: CCG
PbR excluded: No


Liothyronine is NOT recommended for use by the NHS in Lancashire in the following setting:

as an add-on treatment for refractory hypothyroidism despite adequate monotherapy with levothyroxine.

There is insufficient evidence to demonstrate efficacy in the above setting, availability of the drug is limited, adverse events are more prevalent than for levothyroxine monotherapy and there would be a considerable cost pressure to the health economy if prescribed for all patients with normal serum TSH levels and have persistent symptoms.

This colour classification is in agreement with the recommendations contained within the NHS England and NHS Clinical Commissioners guidance document ‘Items which should not routinely be prescribed in primary care: Guidance for CCGs‘ published in November 2017.


LMMG recommendation: Black
Click here to find the definitions for the colour classifications

Reason for decision:  Not recommended for prescribing on the NHS in Lancashire

Supporting documents:

New Medicine Recommendation - Liothyronine (596.9 KiB)





For Blackpool CCG - please use link for more information

Decisions of Lancashire local decision making groups:

NHS Blackburn With Darwen CCG and NHS East Lancashire CCG NHS Blackpool CCG NHS Chorley and South Ribble CCG and NHS Greater Preston CCG NHS Fylde and Wyre CCG NHS Morecambe Bay CCG NHS West Lancashire CCG